Skip to main content
Figure 2 | Stem Cell Research & Therapy

Figure 2

From: Characterization of a novel KCNQ1 mutation for type 1 long QT syndrome and assessment of the therapeutic potential of a novel IKs activator using patient-specific induced pluripotent stem cell-derived cardiomyocytes

Figure 2

Expression of the KCNQ1 gene in LQT1 patient-derived human induced pluripotent stem cell cardiomyocytes. (A) (Left) RT-PCR images covering KCNQ1 cDNA from exon 6 to exon 9 in control and patient human induced pluripotent stem cell cardiomyocytes (hiPSC-CMs). Blue dashed line separates the PCR products of ∆exon8 (above) from ∆exon7 (below). (Right) Sequences of the corresponding PCR products. (B) Quantitative profiling of the wild type (WT) and exon-skipping mRNAs in control and patient hiPSC-CMs. Data presented as mean ± standard deviation. **P <0.01, ***P <0.001, versus control. bp, base pairs; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; LQT1, type 1 long QT syndrome.

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512